Informace o publikaci

Sinonasal malignancy: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up

Autoři	RESTEGHINI C. BAUJAT B. BOSSI P. FRANCHI A. DE GABORY L. HALÁMKOVÁ Jana HAUBNER F. HARDILLO J. A. U. HERMSEN M. A. IACOVELLI N A. MAROLDI R. MATTHEIS S. MOYA-PLANA A. NICOLAI P. ORLANDI E. THARIAT J. TRAMA A. VAN DEN BREKEL M. W. M. VAN HERPEN C. M. L. VERILLAUD B. KINLOCH E. LICITRA L. EVEN C.
Rok publikování	2025
Druh	Článek v odborném periodiku
Časopis / Zdroj	ESMO OPEN
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	https://www.sciencedirect.com/science/article/pii/S2059702924018921?via%3Dihub
Doi	https://doi.org/10.1016/j.esmoop.2024.104121
Klíčová slova	endoscopic surgery; (neoadjuvant) chemotherapy; radiotherapy; proton therapy; sinonasal carcinomas
Popis	The term sinonasal malignancies (SMs) groups together many tumours of variable histology and biological behaviour. This Clinical Practice Guideline (CPG) covers the histotypes included in the fifth edition of the World Health Organization classification of tumours of the nasal cavity, paranasal sinuses and skull base (see Supplementary Table S1, available at https://doi.org/10.1016/j.esmoop.2024.104121) under ‘carcinomas’, ‘adenocarcinomas’ and ‘olfactory neuroblastomas’. Additionally, this CPG covers neuroendocrine carcinomas rising in this area such as small-cell neuroendocrine carcinoma (SCNEC) and large-cell sinonasal neuroendocrine carcinoma (SNEC). Salivary-type malignancies, mesenchymal tumours and mucosal melanoma of the sinonasal tract have been excluded, since dedicated guidelines already exist.